Drug intelligence / Profile preview

CR-1305

Development stage: Preclinical
Lead developer: Coeurative
Modality: Small Molecules
Administration: Intravenous

Overview

CR-1305 is a preclinical-stage small molecule therapeutic candidate being developed by **Coeurative**. It is specifically formulated for **intravenous (IV)** administration to facilitate the **immediate dilation** of coronary arteries, aimed at providing rapid relief for **anginal pain** in patients with **coronary artery disease**. CR-1305 is part of a suite of vasodilatory candidates from Coeurative, which also includes the oral formulation CR-0305. As of the current pipeline status, CR-1305 is categorized as a future planned trial with no first-in-human (FIH) date yet established.

Targets

DNAERN1 (Inositol-requiring enzyme 1 alpha)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))UGT1A10 (UDP-glucuronosyltransferase family 1 member A10)

Beyond the preview

Go deeper on CR-1305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR-1305.